Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis

This study has been terminated.
(side effect and poor clinical outcome)
Sponsor:
Collaborator:
Abbott
Information provided by (Responsible Party):
Peter J. Aronson, MD, Wayne State University
ClinicalTrials.gov Identifier:
NCT01704599
First received: October 3, 2012
Last updated: January 30, 2015
Last verified: January 2015
  Purpose

Vitamins modulating homocysteine affect both TNF-alpha, vascular endothelial growth factor, and theoretically enhance the anti-inflammatory version of NOS thus hopefully increasing the efficacy and reducing the chance of some toxicities of adalimumab as determined by blood testing and EKGs.


Condition Intervention Phase
Psoriasis
Drug: Humira Then Humira plus 3 B vitamins
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI

Resource links provided by NLM:


Further study details as provided by Wayne State University:

Primary Outcome Measures:
  • Number of Particpants With a Categorical PASI (Psoriasis Area and Severity Index) Change [ Time Frame: Weeks 16 and 28 ] [ Designated as safety issue: No ]
    PASI: formula based on body surface areas on head/neck, trunk, both arms & legs with disease quality grading induration, scale and erythema on participants ages 18-65 with moderate to severe plaque psoriasis measured at weeks 16 and 28.


Secondary Outcome Measures:
  • Number of Participants With a Categorical Change in Static Physician Global Assessment (sPGA): [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: No ]
    Number of participants with a category change in Physician static Global Assessment (sPGA): 7 point score from 0 (clear) to 6 measuring amount of surface covered and plaque qualities: thickness & erythema plus scaling. Dynamic score compares baseline with either improvement/ worsening of the same factors measured in the sPGA using the 0-6 scoring range but focused on change. sPGA at weeks 16 AND 28. dynamic PGA to be categoically measured at.weeks16 and 28.

  • Number of Participants With a Categorical DLQI (Dermatology Life Quality Index) Change [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: Yes ]
    DLQI is 10 questions examining impact of skin disease on quality of life: (1) symptoms & feelings (2) daily activities (3) leisure (4) work & school (5) personal relationship (6) treatment. To be administered to adults over 18 years with moderate to severe plaque psoriasis at week 0 (no systemic psoriasis medication);. weeks 16 ( after 16 weeks of adalimumab) and week 28 (after 16 weeks adalimumab then 12 weeks of adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12).

  • Number of Participants With Category Change in Serum VEGF (Vascular Endothelial Growth Factorl) [ Time Frame: At Screening visit, Week 16 on Humira, after another 12 weeks on Humira plus vitamins and if early termination ] [ Designated as safety issue: Yes ]
    Adult particpants ages 18 or older with moderate to severe plaque psoriasis were to have serum VEGF measured at week 0 on no systemic psoriasis medication then at both weeks 16 on adalimumab and at week 28 on adalimumab plus folic acid, B6 and Vitamin B12. Subjects raniked by BMI week 0 low to high

  • Number of Participants Within the Categories of Increasing and Decreasing Serum Homocysteine [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: Yes ]
    Serum homocysteine measured at week 16 after 16 weeks of adalimumab and week 28 after 16 weeks of adalimumaband then 12 weeks of adalimumab plus 5 mg folic acid, 100mg B6 and 1000 mcg of B12 in adults ages 18-65 with moderate to sever plaque psoriasis..

  • Number of Participants With Category Change in Vitamin B12 Blood Level [ Time Frame: At Week 16 and Week 28 ] [ Designated as safety issue: No ]
    Adult participants 18 years or older with moderate to severe plaque psoriasis were to have serum B12 levels measures Weeks 0 (on no systemic psoriasis medication), 16 (on adalimumab) and week 28 (on adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12.

  • Number of Participants Within the Categories of Increasing and Decreasing Serum Vitamin B6 Level [ Time Frame: At Week 16 and Week 28 ] [ Designated as safety issue: No ]
    Serum vitamin B6 levels were to be measured weeks16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab and 12 weeks on adalimuamb, folic acid 5 mg, b6 100 mg and B12 1000 mcg in adult participants with moderate to sever plque psoriasis.

  • Number of Participants With Category Change in Serum Folic Acid Level. [ Time Frame: Weeks 16 and 28 ] [ Designated as safety issue: No ]
    Serum folic acid level in adults ages 18 and older with mild to moderate plaque psoriasis measured at week 16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab plus 12 weeks of adalimumab and daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12.


Other Outcome Measures:
  • Number of Participants in the Categories of Having and Not Having an Adverse Event [ Time Frame: After Week 16 of study ] [ Designated as safety issue: Yes ]

    Worsening psoriasis or development or worsening of measured condition or new pathology not seen by week 16 but developed at weeks 28 or first discoved by telephone call day 70 post study:

    AE Humira only


  • Number of Participants in the Categories of Having and of Not Having a Serious Adverse Event (SAE) [ Time Frame: By Week 16, by Week 28 and by Day 70 post Week 28. ] [ Designated as safety issue: Yes ]
    A serious adverse event is hosptalization or death or pathology leading to early termination of a participant from the study. This was to be reported at anytime during the 28 week study of adult patients ages 18-65 with moderate to severe plaque psoriasis though categorized by Week 16 (on adalimumab alone, by Week 28 (on adalimuamb plus 3 B vitaminsand by day 70 post Week 28.

  • Number of Participants in the Categories of Normalizing, Unchanging and Newly Abnormal Electrocardiograms (EKGs) [ Time Frame: Week 16 and then Week 28 after another 12 weeks on Humira plus vitamins and if early termination ] [ Designated as safety issue: Yes ]
    An electrocardiogram (EKG) is used to evaluate the electrical activity of the heart by converting this activity into line tracings on paper.. Electrodes (small, plastic patches) are placed at certain locations on the chest, arms, and legs. When the electrodes are connected to an EKG machine by lead wires, the electrical activity of the heart is measured, interpreted, and printed out for the doctor's information and further interpretation. This test was to be administered to adults age 18 or older with moderate to severe plaque psoriasis patients at week 0, 16 and week 28 of this study.

  • Number of Participants in Categories or Increasing and Decreasing Changes Within the CBC (Complete Blood Count) [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: Yes ]
    Change in CBC parameter: white blood count or hemoglobin or hematocrit ( as measured week 16 on adalimumab and at week 28 after 12 more weeks on adalimuamb , folic acid, B6 and B12) in adults ages 18-65 with moderate to severe plaque psoriasis.

  • Number of Participants Within the Categories of Increasing and Decreasing Serum Magnesium [ Time Frame: Weeks 16 and 28 ] [ Designated as safety issue: Yes ]
    Serum magnesium (Mg) was to be measured at baseline, Week 16 (on adalimumab) and at week 28 (on adalimumab plus folic acid, vitamins B6 and B12) in adult participants age 18 or older with moderate to severe plaque psoriasis.

  • Number of Participants Within the Categories of Increasing and Decreasing Serum Phosphorus [ Time Frame: Week 16 then Week 28 ] [ Designated as safety issue: Yes ]
    Serum phosphorus (P) levels were to be measured weeks16 and 28 in adult participants age 18 and older with moderate to severe plaque psoriasis at week 0 on no systemic psoriasis medication; week 16 after 16 weeks of adalimumab and at week 28 after 16 weeks of adalimumab plus 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12.

  • Number of Participants Within the Categories of Elevated and Normal Helicobacter Pylori Antibody [ Time Frame: Week 28 after 16 weeks of Adalimumab then 12 of Adalimumab-Vitamins ] [ Designated as safety issue: No ]
    Adult participants age 18 years or older with moderate to severe plaque psoriasis with serum IgG antibodies against Helicobacter pylori bacteria using commercial ELISA assay during the 28 week study.

  • Number of Participants Within the Categories of Positive Urine Pregnancy Test (Urine Hcg) [ Time Frame: At screening ] [ Designated as safety issue: Yes ]
    Women of childbearing years over age 18 with moderate to severe plaque psoriasis on no systemic therapy at week 0 of study.

  • Number of Participants Within the Categories of Increasing and Decreasing Blood Pressure and Pulse Measures: [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: Yes ]
    Blood pressure is the force the heart exerts against the walls of arteries as it pumps the blood out to the body. The unit of measurement is millimeters of mercury (mm Hg). Pulse is the number of times your heart beats per minute. The unit of measurement is beats per minute (BPM). These test measurements compared in adults with moderate to severe plaque psoriasis week 16 after 16 weeks adalimumab and week 28 after 16 weeks adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg vitamin B12.

  • Number of Participants Within Categories of Body Temperature Change [ Time Frame: Weeks 16 and 28 ] [ Designated as safety issue: Yes ]
    Using a thermometer for body temperature on degrees Fahrenheit. Participants to be measured were adults 18 years or older with moderate to severe plaque psoriasis with temperature to be measured at week 16 16 weeks of adalimumab and week 28 after 16 weeks of adalimumab then 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12.

  • Number of Participants Who Fulfilled the Category of Having Height Measured [ Time Frame: Week 0 at Start of Adalimumab ] [ Designated as safety issue: No ]
    Height is the distance from the bottom (soles of feet ) to the top (top of head) of a person when that person is standing in this study using ruler in inches.Participants measured were adults age 18 or older with moderate to severe plaque psoriasis.

  • Number of Participants Within the Categories of Increasign and Decreasing Body Weight [ Time Frame: Week 16 and Week 28 ] [ Designated as safety issue: No ]
    Weight is how heavy a participant is. Weight in pounds of each study adult participant age 18-65 years with moderate to severe plaque psoriasis measured at weeks 16 and compared to week 28 of study.


Enrollment: 8
Study Start Date: January 2009
Study Completion Date: May 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Humira then Humira plus 3 B vitamins

Humira then Humira plus 3 B vitamins

The only arm: After 16 weeks on adalimumab, modulators of homocysteine (oral vitamin B12, oral vitamin B6 or pyridoxine, and oral folic acid) will be added to adalimumab therapy for an additional 12 weeks. At end of this therapy can stop or continue. Telephone call day 70 after formal end of in person study the investigators will assess general health of each subject.

Drug: Humira Then Humira plus 3 B vitamins
Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
Other Names:
  • Humira
  • Adalimumab
  • Vitamin B6
  • Pyridoxine
  • Vitamin B9
  • Folic Acid
  • Vitamin B12
  • Cyanocobalamin

Detailed Description:

This is a pilot study designed to evaluate whether addition of oral vitamin B12, vitamin B6, and folic acid to the use of adalimumab for psoriasis leads to further improvement of a patient's psoriasis and quality of life.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • adults 18 or older
  • moderate to severe plaque psoriasis (>10% BSA)
  • Negative pregnancy test within 7 days before first dose of adalimumab in all women (except surgically sterile or 5 years postmenopausal)
  • subject must sign/date appropriate written informed consent&HIPAA authorization
  • Sexually active subjects of childbearing potential must agree to use medically acceptable contraception during screening and throughout the study
  • no evidence of active or latent tuberculosis based on a negative PPD skin test performed at screening, or within one year of starting this study. Patients with documentation of adequately treated TB may be enrolled
  • Patients PPD positive and CXR negative can be enrolled if they finish appropriate INH prophylaxis prior to enrollment
  • be willing and able to self-administer subcutaneous injections or to have a qualified person available to administer these injections
  • agrees to comply with protocol requirements, attend all regularly study visits and is considered to be a good study subject
  • meets concomitant medication washout requirements
  • willing to use only allowed psoriasis medications and treatments and agree not to start any topical, systemic, or phototherapy for psoriasis during the study period
  • adalimumab naïve

Exclusion Criteria:

  • erythrodermic, pustular, or guttate psoriasis
  • skin conditions other than psoriasis that would interfere with study-related psoriasis evaluations
  • known sensitivity to any component of the study medications
  • Evidence of active infections such as fevers, chills, sweats, or history of untreated Lyme disease and active severe infections within 4 weeks before screening visit, or between the screening and Week 0 visits
  • history of listeriosis, untreated TB, persistent or active infections requiring hospitalization or treatment with IV antibiotics, IV antiretrovirals, or IV antifungals within 30 days of baseline, OR oral antibiotics, antivirals, or antifungals for purpose of treating infection, within 14 days of baseline
  • positive PPD and positive chest x-ray for latent or active tuberculosis
  • positive PPD and negative chest x-ray that have not completed appropriate INH prophylaxis
  • On immune compromising drug or history of immune compromising disorder or immunodeficiency
  • poorly controlled medical condition including, not limited to, unstable cardiovascular disease, poorly controlled diabetes, recent stroke, history of recurrent infections, or any condition for which, in the opinion of the investigators, participation in the study would place the subject at risk
  • hx. congestive heart failure
  • hx. demyelinating CNS disease
  • History of malignancy (other than previously treated localized carcinoma in situ of the cervix or previously treated nonmelanoma skin cancer)
  • history of or ongoing drug or alcohol abuse
  • past or present psychiatric morbidity which may compromise the study
  • Pregnant women, nursing mothers, or planning to become pregnant during study or within 150 days after last dose of study medication. Males planning pregnancy with spouse/partner while in study are to be excluded
  • plans to receive any live vaccines during study
  • history of liver disease
  • Current enrollment in another clinical study/treatment with other experimental drug or approved therapy for experimental use within 30 days prior to Week 0
  • previous enrollment in this study
  • cannot commit to all assessments required by the protocol
  • disorder that compromises the subject to give written informed consent and/or comply with study procedures
  • considered by the investigators to be unsuitable candidate
  • cannot comply with the protocol washout requirements
  • on folic acid in doses over than the minimal daily requirements
  • on vitamins higher than minimal daily requirements (multivitamins are allowed)
  • colon polyps or cancer
  • prior adalimumab therapy
  • on screening plasma Vascular Endothelial Growth Factor level is 140 pg/ml or more
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01704599

Sponsors and Collaborators
Wayne State University
Abbott
Investigators
Principal Investigator: Peter J Aronson, MD Department Dermatology Wayne State University
  More Information

Additional Information:
Humira  This link exits the ClinicalTrials.gov site

Publications:

Responsible Party: Peter J. Aronson, MD, Assistant Professor Department of Dermatology, Wayne State University
ClinicalTrials.gov Identifier: NCT01704599     History of Changes
Other Study ID Numbers: Dermatology 1104009591
Study First Received: October 3, 2012
Results First Received: December 8, 2014
Last Updated: January 30, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Wayne State University:
Psoriasis
Adalimumab
B vitamins
Homocysteine
Folic acid
Cyanocobalamin
Pyridoxine
Vitamin B6
Vitamin B9
Vitamin B12

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Adalimumab
Folic Acid
Hydroxocobalamin
Pyridoxal
Pyridoxine
Vitamin B 12
Vitamin B 6
Vitamin B Complex
Vitamins
Anti-Inflammatory Agents
Antirheumatic Agents
Growth Substances
Hematinics
Hematologic Agents
Micronutrients
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on April 30, 2015